| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 04/03/2003 | WO2002030400A1 Solid preparations |
| 04/03/2003 | WO2002024909A9 Receptor nucleic acids and polypeptides |
| 04/03/2003 | WO2002022166A9 Tweak receptor agonists as anti-angiogenic agents |
| 04/03/2003 | WO2002014369A9 Human kininogen d5 domain polypeptides and their use |
| 04/03/2003 | WO2002000860A3 Novel proteases |
| 04/03/2003 | US20030065382 Means and method for the treatment of coronary artery obstructions |
| 04/03/2003 | US20030065195 Ether compounds |
| 04/03/2003 | US20030065176 Anticoagulant; cardiovascular disorders |
| 04/03/2003 | US20030065149 Stabilized hemoglobin solutions |
| 04/03/2003 | US20030065023 Anticancer agents, viricides, psychological disorders |
| 04/03/2003 | US20030065004 Androgen receptor modulators and methods for use thereof |
| 04/03/2003 | US20030064987 Immunology moderators; interleukin antagonist; anticancer agents |
| 04/03/2003 | US20030064919 Novel polypeptides and polynucleotides encoding same |
| 04/03/2003 | US20030064503 Device |
| 04/03/2003 | US20030064412 123 human secreted proteins |
| 04/03/2003 | US20030064410 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 04/03/2003 | US20030064369 Novel proteins and nucleic acids encoding same |
| 04/03/2003 | US20030064114 For vasodilatation and inhibition of transplant rejection |
| 04/03/2003 | US20030064097 For delivery of drugs, nutrionals, cosmeceuticals and diagnostic agents |
| 04/03/2003 | US20030064068 Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody |
| 04/03/2003 | US20030064052 Useful for maintaining controlled and reliable dosage of the therapeutic agent via pulmonary delivery |
| 04/03/2003 | CA2726702A1 Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| 04/03/2003 | CA2461709A1 Small organic molecule regulators of cell proliferation |
| 04/03/2003 | CA2461666A1 Combination therapies for immune mediated diseases |
| 04/03/2003 | CA2461454A1 Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior |
| 04/03/2003 | CA2461003A1 Human coagulation factor vii polypeptides |
| 04/03/2003 | CA2460953A1 Proteins associated with cell growth, differentiation, and death |
| 04/03/2003 | CA2460777A1 Thrombus/thrombogenesis inhibitors |
| 04/03/2003 | CA2460575A1 Enzymatic conversion of blood group a, b, and ab red blood cells using .alpha.-n-acetylgalactosaminidases and .alpha.-galactosidases with unique substrate specificities and kinetic properties |
| 04/03/2003 | CA2459943A1 Androstanes as androgen receptor modulators |
| 04/03/2003 | CA2424770A1 Solid pharmaceutical preparation |
| 04/02/2003 | EP1298132A1 Hydropyridine derivative acid addition salts |
| 04/02/2003 | EP1297847A2 Anti-CD18 antibodies in stroke |
| 04/02/2003 | EP1297843A1 Method of photoreduction of hemoglobin vesicles |
| 04/02/2003 | EP1297137A2 Gp286 nucleic acids and polypeptides |
| 04/02/2003 | EP1297129A2 Card domain containing polypeptides, encoding nucleic acids, and methods of use |
| 04/02/2003 | EP1297120A2 Liver-specific gene expression cassettes, and methods of use |
| 04/02/2003 | EP1297014A2 Transporters and ion channels |
| 04/02/2003 | EP1296982A1 1-(heteroaryl-phenyl)-condensed pyrazol derivatives as factor xa inhibitors |
| 04/02/2003 | EP1296981A2 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors |
| 04/02/2003 | EP1296977A1 Heteroaryl-phenyl substituted factor xa inhibitors |
| 04/02/2003 | EP1296949A2 Piperidine amides as modulators of chemokine receptor activity |
| 04/02/2003 | EP1296948A2 Novel gamma crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same. |
| 04/02/2003 | EP1296947A1 $g(A) CRYSTALLINE FORM OF PERINDOPRIL TERT-BUTYLAMINE SALT |
| 04/02/2003 | EP1296943A1 Amino acid derivatives and their use as medicines |
| 04/02/2003 | EP1296929A2 Modified forms of pharmacologically active agents and uses therefor |
| 04/02/2003 | EP1296724A1 Bioadhesive composition and methods of preparation and use |
| 04/02/2003 | EP1296709A1 Solubilised protein vaccines |
| 04/02/2003 | EP1296702A1 Neuroprotective peptides |
| 04/02/2003 | EP1296699A1 Therapeutic agents - iii |
| 04/02/2003 | EP1296698A1 Therapeutic agents - ii |
| 04/02/2003 | EP1296697A1 Therapeutic agents - i |
| 04/02/2003 | EP1296681A2 Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl) |
| 04/02/2003 | EP1296674A2 Use of substituted indole compounds for increasing nitric oxide synthase activity |
| 04/02/2003 | EP1296664A2 Propofol for treatment of sepsis |
| 04/02/2003 | EP1296648A1 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 04/02/2003 | EP1296644A2 Systems and methods for treating a mucosal surface |
| 04/02/2003 | EP1296590A2 A personal condition management system |
| 04/02/2003 | EP1246627A4 Polyanhydrides with biologically active degradation products |
| 04/02/2003 | EP1131091B1 Treatment of viral hemorrhagic fever with protein c |
| 04/02/2003 | EP1114051B1 INHIBITORS OF p38 |
| 04/02/2003 | EP0951467B1 SUBSTITUTED NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF p38 PROTEIN KINASE |
| 04/02/2003 | EP0871464B1 Bradykinin analogs as selective thrombin inhibitors |
| 04/02/2003 | EP0865445B1 3-aminoethyl-n-amidino-2,5-dihydropyrrole derivatives having arginine mimetic properties |
| 04/02/2003 | EP0566732B1 Adeno-associated virus-2 basal vectors |
| 04/02/2003 | CN1407989A Antithrombotic compound |
| 04/02/2003 | CN1407986A Novel imidazotriazinones and the use thereof |
| 04/02/2003 | CN1407985A Heterocyclic dihydropyrimidine as potassium path inhibitor |
| 04/02/2003 | CN1407900A Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (MPIF-1) |
| 04/02/2003 | CN1407899A Pharmaceutical combination for treatment of tissue damage owing to arterial irrigation defect |
| 04/02/2003 | CN1407853A Device and method for performing biological modification of fluid |
| 04/02/2003 | CN1407088A Method for establishing hematopoietic stem cells bank by extracting hematopoietic cells from placenta tissues |
| 04/02/2003 | CN1406628A Hemostatics powder and preparation thereof |
| 04/02/2003 | CN1406617A Tablets against allergic purpura |
| 04/02/2003 | CN1406602A Cinese medicine increasing leucocyte and preparation thereof |
| 04/02/2003 | CN1406523A Oral liquid production |
| 04/02/2003 | CN1104420C Salts of ethyl 3-(2-(4-(4-(amino-imino-methyl) phenyl)-4-methyl-2,5-imidazolidin-1-yl) acetylamino)-3-phenyl propionate |
| 04/02/2003 | CN1104418C Benzoheterocyclic derivatives |
| 04/02/2003 | CA2405934A1 Means and method for the treatment of coronary artery obstructions |
| 04/01/2003 | US6541505 Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. |
| 04/01/2003 | US6541503 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
| 04/01/2003 | US6541501 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]-naphthalenyl derivatives with antipsychotic activity |
| 04/01/2003 | US6541499 Benzimidazole derivatives; e.g., 5-hydroxy-1-(3-methoxy-4-((1,2,4-triazol-1-yl)-methyl)benzyl) -2-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-benzimidazole |
| 04/01/2003 | US6541488 Compositions for treating arterial thrombosis and a factor Xa inhibitor |
| 04/01/2003 | US6541475 2-nitrostyryl-1-(naphthylmethyl)sulfone for example |
| 04/01/2003 | US6541471 Useful as a TXA2 receptor antagonist and a 5-HT2 receptor antagonist |
| 04/01/2003 | US6541229 Use for better preservation of red blood cells during storage and increased viability in vivo following transfusion |
| 04/01/2003 | US6540977 Cyanidin compositions and therapeutic and diagnostic uses therefor |
| 04/01/2003 | CA2235951C Novel uses of mammalian ctla-8 and related reagents |
| 04/01/2003 | CA1341426C Process for the manufacture of thrombin inhibitors |
| 03/27/2003 | WO2003025542A2 Immune response associated proteins |
| 03/27/2003 | WO2003025199A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor |
| 03/27/2003 | WO2003025178A1 Novel protein and dna thereof |
| 03/27/2003 | WO2003025151A2 Circadian control of stem/progenitor cell self-renewal and differentiation and of clock controlled gene expression |
| 03/27/2003 | WO2003024973A1 Spirocyclic-6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| 03/27/2003 | WO2003024971A1 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| 03/27/2003 | WO2003024970A1 Compounds which inhibit the release of inflammatory cytokines |
| 03/27/2003 | WO2003024922A1 Hydroxyfattysulfonic acid analogs |
| 03/27/2003 | WO2003024483A1 Potentiator for inhibitory effects on urinary frequency and urinary incontinence |
| 03/27/2003 | WO2003024479A1 Enamel matrix protein compositions for modulating immune response |